Novel Coronavirus (SARS-CoV-2/COVID-19)
After studying how supply chains broke down during the pandemic’s early days and talking with affected health care executives, physicians, engineers and others, Hannah recently outlined in Harvard Business Review steps health care organizations can take to create a more resilient PPE supply…
The Food and Drug Administration authorized for emergency use an armband device that screens people without COVID-19 symptoms for certain potential SARS-CoV-2 biomarkers, such as excessive blood clotting.
AstraZeneca said its AZD1222 COVID-19 vaccine candidate is safe and effective, based on data culled from a phase 3 clinical trial of 32,449 U.S. patients.
The Department of Health and Human Services (HHS) March 19 updated its guidance to hospitals on the reporting of COVID-19-related data.
Precision medicine and population health may seem like contradictory concepts.
The Federal Emergency Management Agency (FEMA) recently updated its policy on “Coronavirus (COVID-19) Pandemic: Medical Care Eligible for Public Assistance
The Food and Drug Administration yesterday updated the health care provider fact sheets for all three monoclonal antibody therapies authorized for emergency use to include information on whether SARS-CoV-2 variants may show resistance to that therapy.
AHA urged the Centers for Medicare & Medicaid Services to extend the five-year window for building medical residency programs to account for the COVID-19 public health emergency.
As part of AHA’s Joining Hands for Greater Impact series, we talk to Atrium Health, American Airlines and Charlotte Douglas International Airport representatives about how they came together to “get shots in arms” in Charlotte, N.C.
AHA’s Living Learning Network open house event will feature insight from UCLA Health leaders on successful strategies and creative solutions being used to efficiently and equitably accelerate the COVID-19 vaccine rollout, as well as lessons learned along the way. As marginalized populations have…